Report Content
Chapter 1 Methodology
1.1 Market definitions
1.2 Base estimates & working
1.3 Forecast calculations
1.4 Data validation
1.5 Data sources
1.5.1 Secondary
1.5.1.1 Paid sources
1.5.1.2 Unpaid sources
1.5.2 Primary
Chapter 2 Executive Summary
2.1 U.S. heparin industry 360° synopsis, 2015-2026
2.1.1 Business trends
Chapter 3 US Heparin Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2015 - 2026
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Growing prevalence of chronic diseases
3.3.1.2 High demand for anti-coagulant products
3.3.1.3 Rising geriatric population in U.S.
3.3.2 Industry pitfalls & challenges
3.3.2.1 High risk of side effects
3.3.2.2 High dependency on porcine
3.4 Growth potential analysis
3.4.1 By product
3.4.2 By application
3.4.3 By distribution channel
3.5 COVID-19 impact analysis
3.6 Porter’s analysis
3.7 Competitive landscape, 2019
3.7.1 Company share analysis, 2019
3.7.2 Company matrix analysis
3.8 PESTEL analysis
Chapter 4 US Heparin Market, By Product
4.1 Key segment trends
4.2 Low molecular weight heparin
4.2.1 Market size, 2015 - 2026 (USD Million)
4.3 Unfractionated heparin
4.3.1 Market size, 2015 - 2026 (USD Million)
Chapter 5 US Heparin Market, By Application
5.1 Key segment trends
5.2 Venous thromboembolism
5.2.1 Market size, 2015 - 2026 (USD Million)
5.3 Atrial fibrillation/flutter
5.3.1 Market size, 2015 - 2026 (USD Million)
5.4 Coronary artery disease
5.4.1 Market size, 2015 - 2026 (USD Million)
5.5 Others
5.5.1 Market size, 2015 - 2026 (USD Million)
Chapter 6 US Heparin Market, By Distribution Channel
6.1 Key segment trends
6.2 Hospital pharmacy
6.2.1 Market size, 2015 - 2026 (USD Million)
6.3 Retail pharmacy
6.3.1 Market size, 2015 - 2026 (USD Million)
6.4 Online pharmacy
6.4.1 Market size, 2015 - 2026 (USD Million)
Chapter 7 Company Profiles
7.1 Competitive dashboard, 2019
7.2 Amphastar Pharmaceutical
7.2.1 Business overview
7.2.2 Financial data
7.2.3 Product landscape
7.2.4 Strategic outlook
7.2.5 SWOT analysis
7.3 Changzhou Qianhong Biopharma Co , Ltd
7.3.1 Business overview
7.3.2 Financial data
7.3.3 Product landscape
7.3.4 Strategic outlook
7.3.5 SWOT analysis
7.4 Fresenius Kabi
7.4.1 Business overview
7.4.2 Financial data
7.4.3 Product landscape
7.4.4 Strategic outlook
7.4.5 SWOT analysis
7.5 Leo Pharma A/S
7.5.1 Business overview
7.5.2 Financial data
7.5.3 Product landscape
7.5.4 Strategic outlook
7.5.5 SWOT analysis
7.6 Nanjing King-Friend Biochemical Pharmaceutical
7.6.1 Business overview
7.6.2 Financial data
7.6.3 Product landscape
7.6.4 Strategic outlook
7.6.5 SWOT analysis
7.7 Pfizer, Inc
7.7.1 Business overview
7.7.2 Financial data
7.7.3 Product landscape
7.7.4 Strategic outlook
7.7.5 SWOT analysis
7.8 Sanofi
7.8.1 Business overview
7.8.2 Financial data
7.8.3 Product landscape
7.8.4 Strategic outlook
7.8.5 SWOT analysis
7.9 Shenzhen Hepalink
7.9.1 Business overview
7.9.2 Financial data
7.9.3 Product landscape
7.9.4 Strategic outlook
7.9.5 SWOT analysis
7.10 Yantai Dongcheng Biochemical Co , Ltd
7.10.1 Business overview
7.10.2 Financial data
7.10.3 Product landscape
7.10.4 Strategic outlook
7.10.5 SWOT analysis
